UroGen Pharma opened lower at $25.90, compared with its previous close of $26.10. In the last trading session, the stock traded between $25.00 and $26.78. It showed an upward intraday trend.
An investment of $100 made 5 years ago in UroGen Pharma is now worth
$ 140.33
Giving a profit of
$ 40.33 (40.33%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
+$0.30 (+1.13%)
Day High
$26.78
Day Low
$25.00
Day Open
$25.90
Prev Close
$26.10
Volume
6,19,847
1W Return
-8.12%
1M Return
-30.98%
3M Return
-44.01%
6M Return
-15.75%
1Y Return
11.71%
Market Cap ($ Mn)
1,295
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-79.72%
EPS (TTM)
$-0.03
1 Week
-8.12%
1 Month
-30.98%
3 Months
-44.01%
6 Months
-15.75%
9 Months
24.86%
UroGen Pharma Q3FY26 Results: Revenue surges 224% YoY to $89 million
Total revenue reached $89 million in Q3FY26, up 224% YoY from $27.5 million. Zesturi net product revenue hit $68 million, growing 35% QoQ on physician adoption. Net loss narrowed to $1.5 million ($0.03/share) vs $33.3 million loss in Q3FY25. Jelmyto revenue fell to $21 million; full-year guidance updated to ~$90 million. Company projects profitability and positive cash flow in Q4FY26.
8 days agoUroGen Pharma to report Q3FY26 results on November 4
UroGen Pharma will report Q3 2026 financial results on November 4, 2026. Earnings release occurs prior to market open, followed by a call at 10:00 am ET. Webcast replay available for approximately 30 days after the live event.
16 days agoHC Wainwright reiterates Buy on UroGen Pharma, keeps $75 target
HC Wainwright & Co. reiterated a Buy rating on UroGen Pharma. Analyst Raghuram Selvaraju maintained the price target at $75. The action signals sustained bullish sentiment from the brokerage.
24 days agoUroGen signs $7M IntraGel deal for TumoCure rights, SRGel platform
UroGen Pharma expands its oncology capabilities through a $7 million investment and licensing agreement with IntraGel Therapeutics. The deal provides UroGen with an exclusive option to commercialize TumoCure for head and neck cancer after Phase 2 trials, alongside access to the versatile SRGel sustained-release platform for up to three additional oncology products. Early Phase 1b data for TumoCure showed favorable safety and anti-tumor activity.
2mo agoOppenheimer raises UroGen Pharma price target to $50
Oppenheimer analyst Leland Gershell maintained an Outperformer rating on UroGen Pharma and raised the price target to $50 from $40, signaling positive sentiment.
3mo agoUroGen secures US patent for recurrent bladder cancer treatment
UroGen Pharma Ltd. secured a Notice of Allowance from the USPTO for a patent covering methods to treat recurrent LG-IR-NMIBC without TURBT, supported by ENVISION and ATLAS trial data, with an expiration date of July 2044. Concurrently, the company is progressing UGN-501, a next-generation oncolytic virus for NMIBC, having received FDA IND clearance to initiate a Phase 1 study in Q4 2026.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in UroGen Pharma is now worth
$ 140.33
Giving a profit of
$ 40.33 (40.33%)
Note: Past profits do not guarantee future returns.
